A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab in Participants with Advanced Solid Tumors
A Study of BMS-986340 Alone and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAT6920
U.S. Govt. ID: NCT04895709
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The main purpose of this study is to test the safety of the investigational drug, BMS-986340, administered alone and in combination with nivolumab. This study will investigate how patients with selected advanced solid tumors tolerate these drugs to identify the highest tolerable dose or the most suitable dose, explore any changes in your tumor, and your general health after receiving multiple doses of BMS-986340 alone or together with nivolumab. BMS-986340 is an immunotherapy antibody and an investigational research drug. Investigational drugs are drugs that are not yet approved by the Food and Drug Administration (FDA) in the United States (US) or by health authorities in other countries. An antibody is a type of protein that your immune system uses to find and destroy infections and potentially harmful cells or particles. An immunotherapy is a treatment that acts by enhancing the function of your immune system. Nivolumab (OPDIVO), is another immunotherapy antibody that is approved in multiple countries, including the United States (US, Dec-2014), the European Union (EU, Jun-2015), and Japan (Jul-2014), for the treatment of certain types of cancer, its use in combination with BMS-986340 is considered investigational. Cancers include colon cancer, rectal cancer, esophageal cancer, cervical cancer, head and neck/oral cancers, lung cancer, and stomach cancer.
Do You Qualify?
Are you age 18 or older? Yes No
Have you been diagnosed with cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator